DARPA backs shelf-stable synthetic blood programme
DARPA’s RAPIID programme is pushing synthetic blood components towards clinical trials and a possible fieldable system by 2029.
DARPA is funding a three-year effort to develop shelf-stable blood components that could reach the battlefield and other emergency settings without the same cold-chain burden as conventional blood products. 1
What RAPIID is trying to solve
The Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) programme aims to combine synthetic oxygen carriers, dried plasma, synthetic platelets, delivery systems and point-of-care diagnostics into a deployable blood-analog system. DARPA says the programme is designed to move beyond laboratory proof of concept and towards regulatory authorisation. 1
The need is logistical as much as medical. Whole blood and its separated components have limited storage lives, while frozen products require careful handling and must be used quickly once thawed. MIT Technology Review reports that RAPIID is backed by $73 million and is targeting field deployment of dried blood products by 2029. 2
From research to clinical trials
DARPA’s official programme page describes a 36-month structure. The first phase focuses on pre-clinical safety, efficacy and manufacturing plans; the second is intended to advance the system into early human trials and commercialisation work. 1
The programme builds on FSHARP, an earlier DARPA effort that supported work on components including KaloCyte’s ErythroMer oxygen carrier and SynthoPlate synthetic platelets. Those technologies remain experimental, and a successful animal result is not the same as approval for routine human use. 2
Our opinion
RAPIID is interesting because it treats blood supply as an infrastructure problem rather than a single miracle-cure problem. The programme has to solve storage, manufacturing, diagnostics, compatibility and regulation at the same time. That is a much harder brief than producing a convincing illustration, but it is also why a durable substitute could matter in ambulances and remote clinics as much as in war zones.